PPARG and early-onset autosomal dominant Alzheimer disease: Among the potential repositioning drugs, peroxisome proliferator-activated receptor-γ (PPARγ) agonists and angiotensin receptor blockers have been spotlighted for Alzheimer’s disease [30].